OncoDNA S.A. news
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED:
“In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of
A UNIQUE WORKFLOW SOLUTION INTEGRATING A PAN-CANCER NEXT-GENERATION SEQUENCING (NGS) PANEL POWERED BY A BIOINFORMATICS SOFTWARE SUITE FOR CUSTOMIZABLE BIOLOGICAL AND CLINICAL INTERPRETATION
ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, TODAY ANNOUNCED THE OFFICIAL LAUNCH OF THE
SYNLAB LABORATORIES TO PERFORM ONCODEEP® BIOMARKER TEST TO HELP DOCTORS DECIDE ON THE MOST EFFECTIVE TREATMENT FOR THEIR CANCER PATIENTS
ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY A PARTNERSHIP WITH SYNLAB, EUROPE’S LEADING CLINICAL LABORATORY AND MEDICAL DIAGNOSTIC SERVICES PROVIDER. INTEGRATING
UNIQUE WORKFLOW SOLUTION INTEGRATING A COMPRENSIVE PAN-CANCER NGS PANEL POWERED BY TWIST BIOSCIENCE AND A BIOINFORMATICS SOFTWARE SUITE
ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY THE LAUNCH OF THE ONCODEEP KIT. THE KIT OFFERS A COMPLETE W
C2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers across Europe. The company will act as a primary lab partner, o
OncoDNA, a genomic and theranostic company specializing in precision medicine, and Bergonié Institute, a non-profit private hospital entirely devoted to fighting cancer, today announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 participating sites across the French Aquitai
THE TWO BELGIAN COMPANIES WILL WORK TOWARDS A BETTER UNDERSTANDING OF NON-SMALL CELL LUNG CANCER BIOLOGY AND CHARACTERIZATION OF THE TUMORS USING AI TECHNOLOGY
Radiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded in medical images with OncoDNA’s expertise in tumor characterization via testing both solid